AU2022407445A1 - Anti-mutant calreticulin (calr) antibodies and uses thereof - Google Patents

Anti-mutant calreticulin (calr) antibodies and uses thereof Download PDF

Info

Publication number
AU2022407445A1
AU2022407445A1 AU2022407445A AU2022407445A AU2022407445A1 AU 2022407445 A1 AU2022407445 A1 AU 2022407445A1 AU 2022407445 A AU2022407445 A AU 2022407445A AU 2022407445 A AU2022407445 A AU 2022407445A AU 2022407445 A1 AU2022407445 A1 AU 2022407445A1
Authority
AU
Australia
Prior art keywords
seq
acid sequence
amino acid
ammo
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022407445A
Other languages
English (en)
Inventor
Rebecca A. Buonpane
Hamza CELIK
Marc C. DELLER
Hsiang-Ting LEI
Patrick MAYES
Leslie Brooke Epling MCQUIRTER
Horacio G. Nastri
Edimara S. REIS
Shaun M. STEWART
Brittney Melissa WASS
Yonghong Zhao
Jing Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AU2022407445A1 publication Critical patent/AU2022407445A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022407445A 2021-12-08 2022-12-07 Anti-mutant calreticulin (calr) antibodies and uses thereof Pending AU2022407445A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163287394P 2021-12-08 2021-12-08
US63/287,394 2021-12-08
US202163288479P 2021-12-10 2021-12-10
US63/288,479 2021-12-10
US202263421052P 2022-10-31 2022-10-31
US63/421,052 2022-10-31
PCT/US2022/081076 WO2023107994A1 (en) 2021-12-08 2022-12-07 Anti-mutant calreticulin (calr) antibodies and uses thereof

Publications (1)

Publication Number Publication Date
AU2022407445A1 true AU2022407445A1 (en) 2024-06-13

Family

ID=84943209

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022407445A Pending AU2022407445A1 (en) 2021-12-08 2022-12-07 Anti-mutant calreticulin (calr) antibodies and uses thereof

Country Status (19)

Country Link
US (1) US20230272055A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444343A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025500796A (cg-RX-API-DMAC7.html)
KR (1) KR20240127992A (cg-RX-API-DMAC7.html)
AU (1) AU2022407445A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241889A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024001654A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024009042A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240277A (cg-RX-API-DMAC7.html)
DO (1) DOP2024000110A (cg-RX-API-DMAC7.html)
GE (1) GEAP202416555A (cg-RX-API-DMAC7.html)
IL (1) IL313366A (cg-RX-API-DMAC7.html)
JO (1) JOP20240122A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024006954A (cg-RX-API-DMAC7.html)
PE (1) PE20241998A1 (cg-RX-API-DMAC7.html)
TW (1) TW202330623A (cg-RX-API-DMAC7.html)
UY (1) UY40062A (cg-RX-API-DMAC7.html)
WO (1) WO2023107994A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202404295B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117467004B (zh) * 2023-10-09 2024-06-21 武汉爱博泰克生物科技有限公司 抗人钙网膜蛋白的兔单克隆抗体及其应用
WO2025096716A1 (en) 2023-11-01 2025-05-08 Incyte Corporation Anti-mutant calreticulin (calr) antibody-drug conjugates and uses thereof
WO2026013015A1 (en) * 2024-07-09 2026-01-15 Merus N.V. Multispecific binding moieties comprising calr and cd3 binding domains
WO2026136827A1 (en) 2024-12-20 2026-06-25 Incyte Corporation Treatment of clonal hematopoietic disorders using kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
WO2016087514A1 (en) 2014-12-02 2016-06-09 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3932952A4 (en) 2019-02-28 2022-11-30 Juntendo Educational Foundation ANTIBODIES BINDING TO TRUNKED MUTANT CALRETICULIN AND DIAGNOSTIC, PROPHYLACTIC OR THERAPEUTIC DRUG FOR MYELOPROLIFERATIVE NEOPLASMA

Also Published As

Publication number Publication date
PE20241998A1 (es) 2024-09-27
US20230272055A1 (en) 2023-08-31
UY40062A (es) 2023-06-30
DOP2024000110A (es) 2024-09-30
CL2024001654A1 (es) 2024-11-04
GEAP202416555A (en) 2024-10-28
TW202330623A (zh) 2023-08-01
CO2024009042A2 (es) 2024-08-08
EP4444343A1 (en) 2024-10-16
MX2024006954A (es) 2024-06-21
JP2025500796A (ja) 2025-01-15
JOP20240122A1 (ar) 2024-05-29
CL2025000229A1 (es) 2025-06-06
IL313366A (en) 2024-08-01
CR20240277A (es) 2024-08-07
WO2023107994A1 (en) 2023-06-15
KR20240127992A (ko) 2024-08-23
CA3241889A1 (en) 2023-06-15
ZA202404295B (en) 2025-02-26

Similar Documents

Publication Publication Date Title
CN111182919B (zh) 抗cd137抗体
EP4444343A1 (en) Anti-mutant calreticulin (calr) antibodies and uses thereof
EP4084825A1 (en) Anti-cd73 antibodies and uses thereof
US9840554B2 (en) Antibodies against platelet-derived growth factor (PDGF)
KR101413451B1 (ko) 사람 il­6에 특이성을 지니는 항체 분자
JP2016517277A (ja) TNFαに対して指向された二重特異的結合タンパク質
JP2016522793A (ja) IL−1βおよび/またはIL−17に対して指向された二重特異的結合タンパク質
JP2014503202A (ja) TNF−α結合性タンパク質
JP2019141084A (ja) Baff及びb7rp1に特異的なタンパク質及びその使用
CN104379603B (zh) Tlr3结合剂
CN112041346A (zh) 用于与抗pd-1抗体组合的抗cd137抗体
JP2024177124A (ja) 抗変異体カルレチクリン(calr)抗体及びその使用
CN118591386A (zh) 抗突变体钙网蛋白(calr)抗体及其用途
TW202140045A (zh) Il-36r訊息特異性阻礙抗體
CN112020517A (zh) 用于与抗pd-l1抗体组合的抗cd137抗体
US20240109971A1 (en) Ccr6 antibodies
KR20180089521A (ko) Tnf 알파에 결합하는 항체 분자
CN113166264B (zh) 一种分离的抗原结合蛋白及其用途
WO2025171447A1 (en) Antibodies for binding ccr6
US20200140548A1 (en) Method for the treatment of immune thrombocytopenia
WO2025096716A1 (en) Anti-mutant calreticulin (calr) antibody-drug conjugates and uses thereof
WO2021051352A1 (zh) 一种分离的抗原结合蛋白及其用途
EA043217B1 (ru) Анти-cd137 антитела
NZ793343A (en) Anti- LAG-3 antibodies and compositions
NZ724413A (en) Methods of reducing basophil levels